Zobrazeno 1 - 10
of 25
pro vyhledávání: '"L.E. Dockery"'
Autor:
C.G. Jackson, K.N. Moore, L. Cantrell, B.K. Erickson, L.R. Duska, D.L. Richardson, L.M. Landrum, L.L. Holman, J.L. Walker, R.S. Mannel, K.M. Moxley, L. Queimado, A. Cohoon, K. Ding, L.E. Dockery
Publikováno v:
Gynecologic oncology. 166(1)
The aim of this study was to examine the tolerability and efficacy of combination bevacizumab rucaparib therapy in patients with recurrent cervical or endometrial cancer.Thirty-three patients with recurrent cervical or endometrial cancer were enrolle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7336b64daf6935a953c7c624c2ca7325
https://pubmed.ncbi.nlm.nih.gov/35491267
https://pubmed.ncbi.nlm.nih.gov/35491267
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
L.E. Dockery, Kai Ding, David W. Doo, Rebecca C. Arend, Kathleen N. Moore, Abby R. Rubenstein, Sarah G. Mashburn, Camille C. Gunderson, Wesley C. Burkett, A.M. Davis
Objectives Patients with epithelial ovarian cancer (EOC) recurring between 6 and 12 months after primary platinum chemotherapy have worse prognosis than those recurring in >12 months. Artificially prolonging the platinum-free interval (PFI) with cyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc72f01f4477f98c9027dc6edd52789d
https://europepmc.org/articles/PMC7081661/
https://europepmc.org/articles/PMC7081661/
Autor:
L.E. Dockery, Kai Ding, Leigh A. Cantrell, Sara K. Vesely, Lisa M. Landrum, Linda R. Duska, Joan L. Walker, Lurdes Queimado, Laura L. Holman, Robert S. Mannel, Britt K. Erickson, Camille Catherine Jackson, Katherine M. Moxley, Kathleen N. Moore, Debra L. Richardson, Andrew J. Cohoon
Publikováno v:
Journal of Clinical Oncology. 39:5527-5527
5527 Background: Treatment options for patients with recurrent cervical and endometrial cancer remain limited. Even with optimum care, median survival has stalled at 12-17 months. The PARP inhibitor rucaparib has demonstrated activity in both BRCA wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91b73d9885f9a2db0c809c768ae6ac61
https://doi.org/10.1200/jco.2021.39.15_suppl.5527
https://doi.org/10.1200/jco.2021.39.15_suppl.5527
Autor:
L.E. Dockery, Joan L. Walker, T. Castellano, M.E. Buechel, J. Gillen, C.R. Washington, K.G. Essel
Publikováno v:
Gynecologic Oncology. 156:e1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e6d54dd4c9ba198f21d04dc5c55b45b
https://doi.org/10.1016/j.ygyno.2019.11.038
https://doi.org/10.1016/j.ygyno.2019.11.038
Autor:
L.E. Dockery, Laura L. Holman
Publikováno v:
DeckerMed Obstetrics and Gynecology.
Treatment of most gynecologic malignancies typically uses a combination of surgical resection of tumor burden followed by chemotherapy. Chemotherapy may also be used as a radiosensitizing agent for diseases such as cervical, vulvar, and vaginal cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c579c42c75ad96e640103dfc784da70f
https://doi.org/10.2310/obg.19168
https://doi.org/10.2310/obg.19168
Autor:
Laura L. Holman, J.M. Ward, Sara K. Vesely, L.E. Dockery, Kathleen N. Moore, Elangovan Thavathiru, Doris M. Benbrook
Publikováno v:
Gynecologic Oncology. 154:e24-e25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01ec0cf1c960fc82299d77eb0414af2d
https://doi.org/10.1016/j.ygyno.2019.03.218
https://doi.org/10.1016/j.ygyno.2019.03.218
Publikováno v:
Gynecologic oncology. 147(3)
The objective of this study was to determine the overall tolerability and toxicity of olaparib capsules among older (≥65years) patients with recurrent ovarian cancer treated on 8 completed prospective trials of olaparib.An ancillary data analysis o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b431ca62083f0606abe15cdb1922ae
https://pubmed.ncbi.nlm.nih.gov/29037805
https://pubmed.ncbi.nlm.nih.gov/29037805
Autor:
Anita Motwani, L.E. Dockery, Laura L. Holman, Kathleen N. Moore, Kai Ding, Mark P. Doescher, Justin D. Dvorak
Publikováno v:
Gynecologic oncology. 149(1)
Objectives Patient navigation programs have been shown to positively impact cancer outcomes for minority populations. Little is known regarding the effects of these programs on American Indian (AI) populations. The purpose of this study is to charact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6377f9b59763a443c074db6369b29289
https://pubmed.ncbi.nlm.nih.gov/29605056
https://pubmed.ncbi.nlm.nih.gov/29605056
Publikováno v:
OncoTargets and therapy
OncoTargets and Therapy, Vol Volume 10, Pp 3029-3037 (2017)
OncoTargets and Therapy, Vol Volume 10, Pp 3029-3037 (2017)
LE Dockery, CC Gunderson, KN Moore Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA Abstract: Rucaparib camsylate (CO-338, AG-014
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1130454fd221680f1806e8efffed8643
https://pubmed.ncbi.nlm.nih.gov/28790837
https://pubmed.ncbi.nlm.nih.gov/28790837